Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.60 +4.4%	$2.20	$0.40 ▼ $3.10	$200.75M	2.05	2.21 million shs	3.71 million shs
GLTO Galecto	$3.49 +2.5%	$3.18	$2.01 ▼ $16.07	$4.50M	1.35	85,372 shs	14,494 shs
KMDA Kamada	$8.02 +2.2%	$7.13	$5.08 ▼ $9.16	$451.41M	0.96	95,889 shs	99,793 shs
PRTK Paratek Pharmaceuticals	$2.23	$2.22	$1.29 ▼ $3.65	$127.82M	1.7	724,253 shs	N/A
VTGN VistaGen Therapeutics	$2.43 -2.4%	$2.29	$1.90 ▼ $4.21	$72.60M	0.61	186,494 shs	218,611 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+4.42%	+4.42%	-3.70%	+388.26%	+98.47%
GLTO Galecto	+2.50%	+1.01%	+3.72%	+50.22%	-72.18%
KMDA Kamada	+2.17%	+3.40%	+14.74%	+32.13%	+35.93%
PRTK Paratek Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VTGN VistaGen Therapeutics	-2.41%	+20.00%	+1.67%	+14.62%	-30.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.2219 of 5 stars	3.5	1.0	0.0	4.7	2.1	1.7	1.3
GLTO Galecto	3.289 of 5 stars	3.5	5.0	0.0	0.0	0.7	1.7	1.3
KMDA Kamada	3.7335 of 5 stars	3.3	3.0	0.0	0.0	2.7	1.7	2.5
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	1.6191 of 5 stars	0.0	5.0	0.0	0.0	1.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	105.13% Upside
GLTO Galecto	3.00	Buy	$10.00	186.94% Upside
KMDA Kamada	2.67	Moderate Buy	$13.00	62.09% Upside
PRTK Paratek Pharmaceuticals	0.00	N/A	N/A	N/A
VTGN VistaGen Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest VTGN, CTMX, PRTK, KMDA, and GLTO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	VTGN VistaGen Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$138.10M	1.52	$0.38 per share	6.88	($0.01) per share	-260.00
GLTO Galecto	N/A	N/A	N/A	N/A	$10.99 per share	N/A
KMDA Kamada	$160.95M	2.87	$0.50 per share	15.97	$4.51 per share	1.78
PRTK Paratek Pharmaceuticals	$160.27M	0.80	N/A	N/A	($3.08) per share	-0.72
VTGN VistaGen Therapeutics	$490K	144.61	N/A	N/A	$2.44 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.48	5.42	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
GLTO Galecto	-$21.44M	-$15.53	N/A	N/A	N/A	N/A	-98.27%	-84.29%	8/11/2025 (Estimated)
KMDA Kamada	$14.46M	$0.29	27.66	25.06	0.95	9.60%	6.31%	4.43%	8/13/2025 (Estimated)
PRTK Paratek Pharmaceuticals	-$63.57M	-$1.10	N/A	∞	N/A	-35.44%	N/A	-40.05%	N/A
VTGN VistaGen Therapeutics	-$51.42M	-$1.66	N/A	N/A	N/A	-6,777.08%	-58.88%	-52.38%	8/12/2025 (Estimated)

Latest VTGN, CTMX, PRTK, KMDA, and GLTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/17/2025	Q4 2025	VTGN VistaGen Therapeutics	-$0.52	-$0.43	+$0.09	-$0.43	$0.18 million	($0.01) million
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/8/2025	Q1 2025	GLTO Galecto	N/A	-$1.92	N/A	-$1.92	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
GLTO Galecto	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.73	1.73
GLTO Galecto	N/A	9.62	9.62
KMDA Kamada	N/A	3.30	1.93
PRTK Paratek Pharmaceuticals	N/A	0.52	0.46
VTGN VistaGen Therapeutics	N/A	6.51	6.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
GLTO Galecto	14.20%
KMDA Kamada	20.38%
PRTK Paratek Pharmaceuticals	53.60%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
GLTO Galecto	10.80%
KMDA Kamada	36.10%
PRTK Paratek Pharmaceuticals	8.00%
VTGN VistaGen Therapeutics	1.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
GLTO Galecto	40	1.32 million	1.18 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
PRTK Paratek Pharmaceuticals	268	57.32 million	52.74 million	Optionable
VTGN VistaGen Therapeutics	40	29.16 million	28.78 million	Optionable

VTGN, CTMX, PRTK, KMDA, and GLTO Headlines

Recent News About These Companies

Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay

July 3, 2025 | msn.com

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

June 25, 2025 | businesswire.com

Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

William Blair Issues Negative Forecast for VTGN Earnings

June 23, 2025 | marketbeat.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript

June 22, 2025 | insidermonkey.com

William Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)

June 20, 2025 | theglobeandmail.com

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges

June 19, 2025 | tipranks.com

What is William Blair's Forecast for VTGN Q1 Earnings?

June 19, 2025 | marketbeat.com

VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair

June 18, 2025 | marketbeat.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...

June 18, 2025 | finance.yahoo.com

Vistagen Therapeutics Reports Progress in Clinical Trials

June 17, 2025 | tipranks.com

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

June 17, 2025 | seekingalpha.com

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

June 17, 2025 | marketbeat.com

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

June 17, 2025 | businesswire.com

Insights into VistaGen Therapeutics's Upcoming Earnings

June 16, 2025 | benzinga.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For

June 16, 2025 | gurufocus.com

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

June 12, 2025 | businesswire.com

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025 | businesswire.com

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

April 17, 2025 | businesswire.com

Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%

April 8, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN, CTMX, PRTK, KMDA, and GLTO Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.60 +0.11 (+4.42%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$2.63 +0.03 (+1.12%)

As of 07:18 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Galecto NASDAQ:GLTO

$3.48 +0.09 (+2.50%)

Closing price 07/10/2025 03:45 PM Eastern

Extended Trading

$3.48 0.00 (0.00%)

As of 07/10/2025 07:43 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Kamada NASDAQ:KMDA

$8.02 +0.17 (+2.17%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$7.98 -0.04 (-0.49%)

As of 07:00 AM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Paratek Pharmaceuticals NASDAQ:PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

VistaGen Therapeutics NASDAQ:VTGN

$2.43 -0.06 (-2.41%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$2.40 -0.04 (-1.44%)

As of 07:17 AM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time